Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence.

The test for subgroup differences was highly significant ( P < .0001), confirming that the type of control treatment substantially influenced the magnitude of mPFS benefit associated with osimertinib.

also in 132,142 other papers

Subgroup analysis by treatment line In the first-line therapy subgroup, the pooled analysis revealed a risk ratio of 1.22 (95% CI = 0.99 to 1.50; P = .0046), indicating a trend toward improved ORR with osimertinib compared with control treatments, although this difference did not reach statistical significance.

also in 111,027 other papers